致康胶囊外用对肛瘘术后的治疗效果研究

Therapeutic Effect of Zhikang Capsules for External Use After Anal Fistula Surgery

目的:探讨致康胶囊外用对肛瘘术后的治疗效果。方法:将2019年10月至2020年12月该院120例肛瘘术后患者按照随机数字表法分为对照组与研究组,每组60例。对照组患者术后对创面予以常规治疗,研究组患者术后对创面予以常规治疗+致康胶囊外用治疗。比较两组患者术后1周、2周和4周创面出血和肉芽组织生长情况评分,创面愈合时间和总体疗效,术后1周、4周创缘组织血管内皮生长因子(VEGF)及血管内皮生长因子受体2(VEGFR-2)阳性表达率,以及创面不良反应发生情况。结果:两组患者术后创面出血和肉芽组织生长情况评分均较治疗前明显降低;研究组患者术后1周、2周和4周的创面出血和肉芽组织生长情况评分明显低于对照组,差异均有统计学意义(P<0.05)。研究组患者创面愈合时间为(25.36±2.74)d,明显短于对照组的(30.28±3.31)d,差异有统计学意义(P<0.05)。研究组患者总有效率为93%(56/60),明显高于对照组的80%(48/60),差异有统计学意义(P<0.05)。两组患者术后4周创缘组织VEGF、VEGFR-2阳性表达率均高于术后1周,研究组患者术后4周创缘组织VEGF、VEGFR-2阳性表达率明显高于对照组,差异均有统计学意义(P<0.05)。研究组、对照组患者不良反应发生率分别为12%(7/60)、7%(4/60),组间的差异无统计学意义(P>0.05)。结论:肛瘘术后外用致康胶囊可控制创面出血,促进肉芽组织生长,缩短创面愈合时间,增强疗效,还可提高创缘组织VEGF、VEGFR-2阳性表达率,且较安全。

OBJECTIVE: To probe into the therapeutic effect of Zhikang capsules for external use after anal fistula surgery. METHODS: Totally 120 patients underwent anal fistula surgery in this hospital from Oct. 2019 to Dec. 2020 were divided into control group and research group via random number table,with 60 cases in each group. The control group was given postoperative conventional therapy for the wound,while the research group was given Zhikang capsules based on the control group. The wound bleeding and granulation tissue growth scores at 1 week,2 weeks and 4 weeks after surgery,the healing time and overall efficacy,the positive expression rates of vascular endothelial growth factor( VEGF) and vascular endothelial growth factor receptor 2( VEGFR-2) in the wound margin tissue at 1 week and4 weeks after surgery,and the incidences of adverse drug reactions were compared between two groups. RESULTS:The postoperative wound bleeding and granulation tissue growth scores of both groups were significantly lower than those of before treatment;the wound bleeding and granulation tissue growth scores of the research group were significantly lower than those of the control group at 1 week,2 weeks and 4 weeks after surgery,with statistically significant differences( P<0. 05). The wound healing time was( 25. 36 ± 2. 74) d in the research group,which was significantly shorter than( 30. 28±3. 31) d in the control group,with statistically significant difference( P<0. 05). The total effective rate of research group was 93%( 56/60),which was significantly higher than that of the control group( 80%,48/60),with statistically significant difference( P < 0. 05). The positive expression rates of VEGF and VEGFR-2 in the wound margin tissue at 4 weeks after surgery were higher than those at 1 week after surgery in both groups,and the positive expression rates of VEGF and VEGFR-2 in the wound tissue at 4 weeks after surgery were significantly higher in the research group than in the control group,with statistically significant differences( P<0. 05).The incidence of adverse drug reactions were respectively 12%( 7/60) and 7%( 4/60) in research group and control group,the difference was not statistically significant( P > 0. 05). CONCLUSIONS: The external use of Zhikang capsules after anal fistula surgery can control the wound bleeding,promote the granulation tissue growth,shorten the wound healing time,enhance the clinical efficacy,also increase the positive expression rate of VEGF and VEGFR-2 in the wound margin tissue with higher safety.